(Indiana University) Women’s responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month’s Cancer Biology & Therapy.

Further information:

Article source

Related posts:

1. Effective prostate cancer treatment discovery
2. ‘Microtentacles’ on tumor cells appear to play role in how breast cancer spreads
3. Unpacking condensins’ function in embryonic stem cells
4. New subtype of breast cancer responds to targeted drug
5. Researchers fishing for cancer cure discover active DHA derivatives